POINT Biopharma Global Inc.: auditor change — POINT Biopharma Global auditor Armanino resigns; Deloitte & Touche appointed as new independent auditor

POINT Biopharma Global Inc.

Armanino resigned as auditor effective upon filing of Q2 2023 10-Q due to its decision to cease public company audit services.
No disagreements or reportable events between the Company and Armanino during the past two fiscal years or subsequent interim period.
Audit Committee and Board approved engagement of Deloitte & Touche as independent auditor for fiscal year ending December 31, 2023.
No prior consultations with Deloitte on accounting principles, transactions, or audit opinions during the prior two years.
Armanino filed a letter with the SEC agreeing with the Company's statements regarding the resignation.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

POINT Biopharma Global Inc. engaged Deloitte & Touche LLP as its auditor.

Action: engagement
Auditor: Deloitte & Touche LLP

Exact text from the filing

On August 3, 2023, the Audit Committee approved, and the Board ratified, the engagement of Deloitte & Touche LLP (“Deloitte”) and appointed Deloitte as the Company’s independent registered public accounting firm to audit the Company’s consolidated financial statements for the fiscal year ending December 31, 2023, subject to the execution of an engagement letter.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Armanino LLP resigned as auditor of POINT Biopharma Global Inc..

Action: resignation
Auditor: Armanino LLP
Successor: Deloitte & Touche LLP

Exact text from the filing

On July 28, 2023, POINT Biopharma Global Inc. (the “Company”) was notified by Armanino LLP (“Armanino”), the Company’s independent registered public accounting firm, of its decision to cease providing financial statement audit services to public companies and therefore it would be resigning as the Company’s independent registered public accounting firm.

View on SEC.gov

Browse all auditor changes →

Source: SEC EDGAR

accession 0001811764-23-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.